rohan
healthy soch
New Delhi, December 24, 2019:
The US Department of Health and Human Services has identified hypoglycemia as one of the top three preventable and measurable adverse drug events in a recent article published in the December 11 issue of the Journal of Clinical Endocrinology and Metabolism.
Hypoglycemia is defined in
- Level 1: Glucose < 70 mg/dL and ≥ 54 mg/dL
- Level 2: Glucose < 54 mg/dL; needs immediate action.
- Level 3: A severe event characterized by altered mental and/or physical status requiring assistance.
Remember the three measures:
Measure 1:
Identify high risk patients
- First assess if the patient has experienced a previous Level 2 or Level 3 hypoglycemic event within the past year. If not, then proceed to;
- Second, if the patient has a prescription for insulin and/or insulin secretagogues and has an A1c < 7% documented within the past 6 months. If not, then proceed to;
- Third, if the patient has a prescription for insulin and/or insulin secretagogues and at least one relevant comorbidity.
Measure 2: Educate patients (65+) and care givers who are at greater risk for hypoglycemia
Measure 3: Encourage patients to report hypoglycemic events
healthysoch
